Leveraging the holistic benefits of biosimilars in Europe–part 2: how payers can safeguard the future of a healthy biosimilar market environment

J Mestre-Ferrandiz, M Czech, JS Smolen… - Expert Review of …, 2024 - Taylor & Francis
Introduction Biosimilars have improved access to biologic medicines; however, historical
thinking may jeopardize the viability of future markets. Areas covered An expert panel of …

Biosimilars of anti-vascular endothelial growth factor for ophthalmic diseases: A review

NM Bressler, PK Kaiser, DV Do, QD Nguyen… - Survey of …, 2024 - Elsevier
The development of intravitreally injected biologic medicines (biologics) acting against
vascular endothelial growth factor (VEGF) substantially improved the clinical outcomes of …

[HTML][HTML] Biosimilar Medicines: From Development Process to Marketing Authorization by the EMA and the FDA

C Amaral, AR Rodrigues, F Veiga, V Bell - Applied Sciences, 2024 - mdpi.com
Biosimilars are a new category of medicines that have revolutionized the treatment of
patients with life-threatening conditions, such as cancer and autoimmune diseases. A …

[HTML][HTML] Biosimilars in the Era of Artificial Intelligence—International Regulations and the Use in Oncological Treatments

TG Bas, V Duarte - Pharmaceuticals, 2024 - pmc.ncbi.nlm.nih.gov
This research is based on three fundamental aspects of successful biosimilar development
in the challenging biopharmaceutical market. First, biosimilar regulations in eight selected …

Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics

A Tandulje, P Varpe, P Chaugule, RS Raghuvanshi… - Seminars in …, 2024 - Elsevier
Biological oncology agents are vital in cancer care, but their exorbitant expenses present
obstacles for patients, families, healthcare professionals, and insurance providers. The …

Research and pilot analysis of bevacizumab repurposing potential and its impact in clinical practice

A Ivanov, V Getova-Kolarova, V Belcheva… - Biotechnology & …, 2024 - Taylor & Francis
Repurposing of drugs is a strategy for discovering new uses for already authorized or tested
medicines outside their original indications. Bevacizumab is humanized antibody, observed …

Optimising oncology drug expenditure in Ireland

R Kieran, M Hennessy, K Coakley, H O'Sullivan… - Irish Journal of Medical …, 2024 - Springer
A combination of improvements in patient survival, increasing treatment duration, and the
development of more expensive agents has led to a doubling of per-capita spending on …

Provider perceptions of barriers to biosimilar utilization in community oncology practices

O Briggs, CM Brown, P Indurlal, JS Garey… - Journal of the American …, 2024 - Elsevier
Background Biosimilars reduce the burden of cost on patients and payers, and so doing,
increase access to life-saving care. However, biosimilar uptake in the US has been …

Regulatory Considerations of Biosimilars in Cancer

L Nagar, A Saini, N Gulati, N Solanki… - Biosimilars for Cancer …, 2024 - Springer
In the fast-evolving field of cancer treatment, the introduction of biosimilars has brought
about significant changes in the available therapeutic options. Biosimilars, which are …

[HTML][HTML] Quantification of the Cellular Content of Platelet Rich Plasma Harvested After Injection of Filgrastim Versus Pegfilgrastim Biosimilars: A Prospective, Single …

M Abbasian, E Branch, A Parsa, J Truett… - Journal of Cartilage & …, 2024 - Elsevier
Abstract Background Hematopoietic stem cells (HSCs) are primitive cells that often appear
in peripheral blood (PB) following mobilization events from bone marrow due to stress …